Showing 6101-6110 of 7374 results for "".
- Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Directorhttps://practicaldermatology.com/news/valeant-pharmaceuticals-appoints-thomas-w-ross-sr-lead-independent-director/2458532/Valeant Pharmaceuticals International, Inc.'s Board of Directors appointed Thomas W. Ross, Sr. as its lead independent director. Mr. Ross, who has been a member of Valeant's Board since March 8, 2016, serves on the Board&#
- UCB: Investigational Bimekizumab Helps Psoriatic Arthritis in Phase 1Bhttps://practicaldermatology.com/news/ucb-investigational-bimekizumab-helps-psoriatic-arthritis-in-phase-1b/2458534/Bimekizumab, in development by UCB, has shown promise for the treatment of psoriatic arthritis (PsA) in Phase 1B studies. For the study, a total of 52 PsA patients inadequately controlled with at least one disease-modifying anti-rheumatic drug (DMARD) and/or one biologic were randomized to
- New Psoriasis Drug Taltz Shows Benefit Through 60 Weekshttps://practicaldermatology.com/news/new-psoriasis-drug-taltz-shows-benefit-through-60-weeks/2458536/Three new studies demonstrate the efficacy and safety of Eli Lilly's Taltz® (ixekizumab) through 60 weeks among patients with moderate-to-severe plaque psoriasis. The findings appear in the
- Derm Salaries On The Risehttps://practicaldermatology.com/news/derm-salaries-on-the-rise/2458537/Starting salaries for dermatologists spiked 13 percent in the last 12 months, according to a new report from Merritt Hawkins. The average annual salary for a dermatologist in 2015-2016 was $444,000, with a low of $250,00 and a high of $650
- Acne Scars: Survey Highlights the Negative Ways Acne and Acne Scars Can Affect Confidencehttps://practicaldermatology.com/news/acne-scars-survey-highlights-the-negative-ways-acne-and-acne-scars-can-affect-quality-of-life/2458539/Ninety-nine percent people would have more confidence if their acne and acne scars were gone, according to a new survey for Suneva Medical. When it comes to skin issues, respondents feel that acne scars are worse than having acne, eczema or rosacea. Nearly half of adults still have
- Kate Bosworth Partners with Allergan for ACZONE® Gel, 7.5% Launchhttps://practicaldermatology.com/news/kate-bosworth-partners-with-allergan-for-aczone-gel-75-launch/2458540/Actress, producer and model Kate Bosworth is the new face of Allergan plc’s ACZONE® (dapsone) Gel, 7.5%. ACZONE® Gel, 7.5% is a once-a-day prescription topical treatment for acne in patients 12 years of age and older. It was approved
- Dupilumab with Topical Corticosteroids (TCS) Superior to TCS Alone in Long-term Atopic Dermatitis Studyhttps://practicaldermatology.com/news/dupilumab-with-topical-corticosteroids-tcs-superior-to-tcs-alone-in-long-term-atopic-dermatitis-study/2458541/Treatment with investigational dupilumab in combination with topical corticosteroids (TCS) significantly improved measures of overall disease severity, according to one-year results of the LIBERTY AD CHRONOS study. Reported by Regeneron Pharmaceuticals, Inc. and Sanofi, the phase 3 study involved
- Dermira's DRM04 Shows Promise for Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermiras-drm04-shows-promise-for-primary-axillary-hyperhidrosis/2458543/Dermira’s DRM04 may help put the brakes on primary axillary hyperhidrosis, according to topline results from two Phase 3 trials. Based on the results of these trials, Dermira plans to submit a New Drug Application to the US Food and Drug Administ
- FDA Approves Juvéderm Volbella XC for Use in Lips and Perioral Rhytidshttps://practicaldermatology.com/news/fda-approves-juvderm-volbella-xc-for-use-in-lips-and-perioral-rhytids/2458546/Allergan plc, has received FDA approval to market Juvéderm Volbella XC for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21. In clinical trials, Juvéderm Volbella XC was found to effecti
- Allergan's TEFLARO® OK'd for Pediatric Patientshttps://practicaldermatology.com/news/allergans-teflaro-oked-for-pediatric-patients/2458547/Allergan’s TEFLARO® (ceftaroline fosamil) is now indicated for pediatric patients, making it the first branded IV antibiotic approved for this population in more than a decade. The U.S. Food and Drug Administration (FDA) appr